Abstract: The present invention is directed to hydrolytically stabilized maleimide-functionalized water soluble polymers and to methods for making and utilizing such polymers and their precursors.

Abstract: Textile treatment agents and/or capsules comprising a polymer having antiadhesive action against microorganisms which adhere to a textile substrate, methods of treating textile substrates therewith and the textile so treated, wherein the polymer comprises a polymeric structural element selected from the group consisting of polyesters, polysaccharides, polyethers, polyurethanes, polyureas, polyamides, and heteropolymers thereof.

Abstract: The present invention broadly relates to the field of protein modification and more specifically, water soluble block polymers, their attachment to drugs, and methods of making and use thereof.

Abstract: The use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerization of the aforementioned monomers of active a-amino acids in an aqueous solvent and can be resolubilized in the solvent.

Abstract: The present invention relates to polymers functionalized by an aminooxy group or a derivative thereof, conjugates, wherein the functionalized polymers are covalently coupled with a protein by an oxime linking group, a process for preparing the functionalized polymers, a process for preparing the conjugates, functionalize polymers as obtainable by the process of the present invention, conjugates as obtainable by the process of the present invention, and pharmaceutical compositions comprising at least one conjugate of the present invention and the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.

Abstract: Disclosed herein are novel block (co)polymers comprising from 35 to 100 wt. %, based on the weight of the block containing them, of silicone monomers chosen from a given list. Also disclosed herein are cosmetic and pharmaceutical compositions containing said polymers, as well as a method of cosmetic treatment employing them, and a method of preparation of said polymers.

Abstract: Composition containing, in a physiologically acceptable medium, a tensioning polymer and organic-mineral hybrid particles. Process, particularly for facial skin, in particular wrinkled skin, involving the application of the invention composition to the skin.

Abstract: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.

Abstract: Silane-modified polymeric amines having a weight average molecular weight of 10,000 to 1,000,000 g/mol, and comprising at least one structural unit of the formula (I) which unit may comprise part of the main polymer chain or may be bound to the main polymer chain by an anchor group: wherein X represents a bond or a —(CR4R5)n— group; Z represents a —CONH—, —(CH2)m—O—, or —(CH2)o—CH(OH)—(CH2)p—(O)q— group; m represents a number 1 to 6; o represents a number 0 to 6; p represents a number 1 to 6; q represents a number 0 or 1; r represents a number 0 or 1; R1, R2, and R3 each independently represent an alkyl, an OH, or an O-alkyls; R4 and R5 each independently represents an H or an alkyl; and n represents a number 1 to 20; methods for their preparation, biocidal formulations containing the same and uses therefore.

Abstract: Polymers (i.e. polyesters, polyamides, polythioesters, polyanhydrides, or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g., amoxicillin) and a beta-lactamase inhibitor (e.g., clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor (or a pharmaceutically acceptable salt thereof) to a host are also provided.

Abstract: Disclosed is a method for lowering elevated uric acid levels in a patient having a plasma level of uric acid (pUAc) of more than about 6 mg/dL, the method consisting of administering to said patient an intravenous injections every 2 to 4 weeks of about 8 mg PEG-uricase.

Abstract: The present invention describes compositions and methods for sorbing and/or destroying dangerous substances such as chemical and biological warfare agents. The present invention relates to dendritic polymers, specifically, to quaternary ammonium functionalized dendritic polymers and N-Halamine functionalized dendritic polymers. Such dendrimers are useful for the capture and neutralization of biological and chemical warfare agents.

Abstract: The present invention relates to the synthesis of a haemocompatible polymer, consisting of a polyurethane bound covalently to sulphated hyaluronic acid. These sulfated derivatives have anticoagulative, non-thrombogenic, antiviral and anti-inflammatory properties. They also have the ability to inhibit platelet adhesion, aggregation and activation. The invention is particularly advantageous in resisting the enzyme hyaluronidase, therefore ensuring anti-coagulant activities for longer periods of time when compared to similar compounds. This biocompatible polymer material is well suited for surgical or other medicinal uses.

Abstract: The present invention relates to a skin patch comprising a matrix adhering to the skin and containing at least one active cosmetic substance and a combination with a skin wrapping to generate an effective compression for the treatment of cellulite and/or striae.

Abstract: The present invention is directed to medical devices and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry.

Abstract: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the overall structure of the copolymer comprises an inner core region that includes the central core and the inner polypeptide segment, while the outer core region is hydrophilic in nature. The multi-arm copolymer of the invention is particularly useful for delivery of biologically active agents that can be entrapped within the inner core region.

Abstract: The present invention relates to an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block with a terminal hydroxyl group wherein the terminal hydroxyl group of the hydrophobic bock is substituted with a tocopherol or cholesterol group. It also relates to polymeric compositions capable of forming stable micelles in an aqueous solution, comprising the amphiphilic block copolymer and a polylactic acid derivative wherein one or more ends of the polylactic acid are covalently bound to at least one carboxyl group.

Abstract: Contact killing antimicrobial articles, devices and formulations are described which kill microorganisms on contact. The articles, devices or formulations contain a non-leaching antimicrobial material which is a unique combination of an organic matrix having biocidal metallic materials non-leachably associated with the matrix. The antimicrobial material may used to form an antimicrobial coating or layer on a surface of the article or device, or may be dispersed in a vehicle or carrier to form a topical antiseptic or disinfectant, or solid shape having contact killing antimicrobial properties. When a microorganism contacts the article, device, or formulation, the biocidal metallic material is transferred to the microorganism in amounts sufficient to kill it.

Abstract: This invention is directed to graft materials for implanting, transplanting, replacing, or repairing a part of a patient and to methods of making the graft materials. The present invention is also directed to stent grafts and endoluminal prostheses formed of the graft materials. More specifically, the present invention is a graft material which includes polymeric sheet comprising holes. The graft material also comprises an ECM disposed in the holes of the polymeric sheet. The polymeric sheet of the graft material could be a textile or a porous polymer.

Abstract: A biocompatible stable composition containing a hydrophobic drug, such as paclitaxel. The composition, which forms a syringeable polymeric micellar solution in aqueous or body fluids, is a freeze-dried product comprising a hydrophobic drug, i.e. paclitaxel, and an amphiphilic block copolymer wherein a hydrophobic group having affinity or attraction with the hydrophobic drug, such as paclitaxel, is incorporated on its end.

Abstract: Water soluble activated polymers are provided containing an active ethyl sulfone moiety having a reactive site located at the second carbon from the sulfone group. In an embodiment, a poly(ethylene glycol) (PEG) derivative is disclosed that is activated with the active ethyl sulfone moiety for selective attachment to thiol moieties on molecules and surfaces. The activated PEG is water soluble, hydrolytically stable for extended periods, and forms hydrolytically stable linkages with thiol moieties. The linkages generally are not reversible in reducing environments. The PEG derivative is useful for modifying the characteristics of substances including modifying biologically active molecules and surfaces for biocompatibility.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.

Abstract: A method for preparation of block copolymeric nanoparticles is disclosed. The method is a single-step preparation in which block copolymeric nanoparticles are produced directly from a solution of crosslinkable block copolymer in a carrier medium. The block copolymeric nanoparticles thus formed have at least one crosslinked polymeric phase.

Abstract: A synthetic polymer comprises a cationic recurring unit and a crosslinking unit, wherein the crosslinking unit comprises at least a first degradable unit (preferably acid-labile) and at least a second degradable unit (preferably hydrolyzable). A carrier composition comprising the synthetic polymer and a bioactive agent is useful for the delivery of the bioactive agent into the nuclei of the cells.

Abstract: A dental composite material that comprises a polyhedral oligomeric silsesquioxane is disclosed. The dental composite material is useful for a variety of dental materials, treatments, and restorative functions including crown and bridge materials, fillings, adhesives, sealants, luting agents or cements, denture base materials, orthodontic materials and sealants, and other dental restorative materials.

Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: Provided is a complex comprising cisplatin encapsulated therein in a form in which a chlorine ion thereof is ligand-exchanged with a carboxyl anion of a block copolymer comprising poly(ethylene glycol)-poly(glutamic acid). This complex can be a medicinal preparation to which a novel dosage form decreased in toxicity can be applied.

Abstract: The present invention relates to quaternized polyamidoamines which have at least one structural unit of the formula VII in which R1, R2, R4 are straight-chain or branched organic radicals optionally containing heteroatoms; R5 is hydrogen or alkyl, R7 is hydrogen or alkyl or two radicals R7 together form a radical having a meaning given for R4, b is an integer from 0 to 50, and c is an integer from 1 to 50. The invention also relates to the preparation of the quaternary polyamidoamines, to compositions which comprise these compounds, and to the use thereof for cosmetic and pharmaceutical purposes, and in the fields of crop protection and textile dyeing. The present invention also relates to the use of quaternized polyamidoamines of the ionene type as biostatic or biocide and thus also biocidal compositions based on quaternized polyamidoamines.

Abstract: An aromatic polyanhydride having a repeating unit with structure (I) wherein Ar is a substituted or unsubstituted aromatic ring and R is a difunctional organic moiety substituted on each Ar ortho to the anhydride group. Ortho-substituted bis-aromatic dicarboxylic acid anhydride monomers and ortho-substituted bis-aromatic dicarboxylic acid intermediates thereof are also disclosed, as well as implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic oral dosage forms and treatment methods.

Abstract: The present invention relates to a composition and use of polymeric urethane esters quats as an active ingredient for skin and hair contacting personal care compositions and products related thereto. These compositions are generally produced by the reaction of a trialkanolamine with a hydroxy fatty acid to produce a trialkanolamine fatty acid ester, which is then polymerized with a diisocyanate and in preferred embodiments, further reacted with a quaternizing agent to produce preferred quaternized compositions according to the present invention.

Abstract: Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.

Abstract: The invention relates to cross-linked copolymers based on non cross-linked polycarboxylic copolymers, said non cross-linked copolymers containing at least one polysaccharide. The invention also relates to a process for the preparation of these copolymers and their use in particular as a support in pharmaceutical compositions.

Abstract: Production of a hyaluronic acid gel, which comprises keeping hyaluronic acid in water at a hyaluronic acid concentration of at least 5 wt % in the presence of an acid component in an amount at least equimolar with the carboxyl groups in the hyaluronic acid.

Abstract: A gel material and medical articles including such material, wherein the transparent gel material includes a polymerized poly(alkylene oxide) macromonomer that, prior to polymerization, is free-radically polymerizable, multifunctional (preferably difunctional), and has an average molecular weight of at least about 2000.

Abstract: Antineoplastic dendritic polymer conjugates which are useful drug delivery systems for carrying antineoplastic agents to malignant tumors are prepared by obtaining a dendritic polymer having functional groups which are accessible to an antineoplastic agent capable of interacting with the functional groups, and contacting the dendritic polymer with the antineoplastic agent. The preferred platin-based analogues of the antineoplastic agents conjugated to the dendritic polymer may be administered intravenously, orally, parentally, subcutaneously, intramuscularly, intraarterially or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The antineoplastic dendritic polymer conjugates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo.

Abstract: The invention concerns phosphorus-containing dendrimers and their uses, as gene transfection agents, in vitro and in vivo, including in the treatment of human and animal diseases. These agents or vectors are in particular suited for delivering to appropriate target cells, nucleic acid sequences of interest.

Abstract: Novel arylisothiocyanate compounds are described that are useful for activating alcohol-containing macromolecules, for example polyethyleneglycols and cellulose, for covalent linkage to amino-groups of biomolecules, for example polypeptides such as antibodies, enzymes, and proteins.

Abstract: A temperature-responsive polymer and polymer material which has ester bond(s) and/or acid amide bond(s) respectively at one or more sites in the side chain and can be arbitrarily controlled by varying the side chain is provided.

Abstract: Water-in-oil emulsions, compositions, and methods that include a vinyl polymer having a pKa of less than 4 that includes anionic group-containing side chains and alkyl-Y-containing side chains, wherein Y is O or NR, wherein R is hydrogen or methyl, and wherein the alkyl group of the alkyl-Y-containing side chain has at least 4 carbon atoms on average in a cyclic, branched-, or straight-chain configuration and optionally including one or more heteroatoms.

Abstract: AGE precursors can be removed from blood, plasma or PBS buffer using a modified polymeric shaped body that can be produced by reaction of diaminoguanidine and/or triaminoguannidine with a staring polymeric shaped body carrying R—X residues, where R is an alkylene group that may or may not be substituted with a hydroxyl group and contains from 1 to 3 carbon atom, and X is a group that is substituted during the reaction by carrying residues Y, on to with diaminoguanidine, or with a starting polymeric shaped body during the reaction which diaminoguanidine and/or triaminoguannidine are added during the reaction.

Abstract: Novel water-soluble or water-dispersible amphiphilic cationic associative polymers, a process for preparing them and their use in compositions for topical application, such as for cosmetic use, as thickeners, and the compositions comprising these polymers.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to the method of using polysulphated cyclodextrins or addition salts thereof for use in the treatment of arthrosis, and pharmaceutical compositions thereof.

Abstract: The present invention provides an apparatus and method for controlled release of a fumigant into a wooden structure to prevent decay of that structure. According to the present invention, a fumigant in an ampule or container is inserted into the wooden structure. The ampule or container is made of a polymeric material that does not react with the fumigant, but having walls which are permeable to the fumigant such that, when inserted into the wooden structure, the rate of release of the fumigant through the walls of the ampule is slow enough to continuously treat and arrest decay of the wooden structure, particularly decay caused by fungi, over extended periods of time (i.e., 1, 5, 7, 10, 15, 20 or 30 years). The rate of release of the fumigant can be controlled by the type of fumigant, the shape of the container, the specific polymer used to make the container, and by the thickness of the container wall.

Abstract: A new oligomer based on alternating fumaric acid and poly(ethylene glycol) (PEG) units is provided. The oligo(PEG fumarate) (OPF) may be functionalized by modification with a biocompatible organic group. Further, the OPF may be cross-linked using radical polymerization in the presence of either a chemical or photo initiator. A cross-linked OPF gel has a swelling behavior that is tunable dependent on the molecular weight of PEG. A cross-linkable PEG macromer, as exemplified by oligo(PEG fumarate), has unsaturated double bonds, for example in the fumaryl groups, along its macromolecular chain that allows for the preparation of hydrogels with tailored structure and properties.

Abstract: PEG and related polymer derivatives having weak, hydrolytically unstable linkages near the reactive end of the polymer are provided for conjugation to drugs, including proteins, enzymes, small molecules, and others. These derivatives provide a sufficient circulation period for a drug-PEG conjugate and then for hydrolytic breakdown of the conjugate and release of the bound molecule. In some cases, drugs that previously had reduced activity when permanently coupled to PEG can have therapeutically suitable activity when coupled to a degradable PEG in accordance with the invention. The PEG of the invention can be used to impart water solubility, size, slow rate of kidney clearance, and reduced immunogenicity to the conjugate. Controlled hydrolytic release of the bound molecule in the aqueous environment can then enhance the drug delivery system.

Abstract: Methods of producing an intraocular lens in vivo comprise preparing a composition of discrete water soluble macromolecular particles, mixing the composition with a water soluble photoinitiator and forming an opthalmically acceptable aqueous solution having a refractive index of at least 1.39, injecting the resulting aqueous solution into the capsular bag of an eye, and initiating crosslinking between the macromolecular particles by irradiation of a wavelength in the range of about 380 to 700 nm to create a lens in the capsular bag.

Abstract: Disclosed is a thermogelling biodegradable aqueous polymer solution useful in providing a bioactive agent delivery system. The present invention provides a thermogelling biodegradable aqueous polymer solution with a polyethylene glycol (PEG) block and a biodegradable polyester block, where the blocks are linked to form a polymer of a general structure comprising the formula of An(B), where n is greater than 2 and A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and A is different from B.

Abstract: Methods for coating different regions of an implantable device are disclosed. An embodiment of the method includes dipping a first portion of the implantable device into a first coating substance, and then centrifuging the implantable device to provide an even coating. Next, a second portion of the implantable device is dipped into a second coating substance, and the implantable device is again centrifuged, resulting in an even second coating. In another embodiment, a first coating substance is applied to an interior surface of a cylindrical implantable device, such as a stent or graft, and a second coating substance is applied to an exterior surface. A centrifuge step is performed so that the first coating substance is preferentially and uniformly applied on the interior surface of the implantable device and the second coating substance is preferentially and uniformly applied on the exterior surface of the implantable device.